raloxifene hydrochloride has been researched along with Low Bone Density in 42 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (2.38) | 18.7374 |
| 1990's | 1 (2.38) | 18.2507 |
| 2000's | 24 (57.14) | 29.6817 |
| 2010's | 15 (35.71) | 24.3611 |
| 2020's | 1 (2.38) | 2.80 |
| Authors | Studies |
|---|---|
| Amugongo, SK; Donnelly, E; Johnson, ML; Kimmel, DB; Lane, NE; Taylor, EA; Yao, X | 1 |
| Barry, MJ; Cooke, M; Denberg, TD; Fitterman, N; Forciea, MA; Harris, RP; Humphrey, LL; Kansagara, D; McLean, RM; Mir, TP; Qaseem, A; Schünemann, HJ | 1 |
| Farbodara, T; Haghverdi, F; Mortaji, S; Saidi, N; Soltani, P | 1 |
| Burge, R; Flynn, JA; Fujiwara, S; Graham-Clarke, P; Hamaya, E; Sato, M | 1 |
| Eastell, R; Gossiel, F; Jacques, RM; Naylor, KE; Peel, NF | 1 |
| Kobayashi, T; Matsumoto, M; Miyamoto, K; Miyamoto, T; Morita, M; Nakamura, M; Oike, T; Sato, Y; Tando, T; Watanabe, R | 1 |
| Ichikawa, S; Kanda, T; Kasama, S; Kumakura, H; Kurabayashi, M; Murakami, M; Sumino, H; Takahashi, T; Takayama, Y | 1 |
| Alexander, IM | 1 |
| Gorai, I; Hattori, S; Iwaoki, Y; Tanaka, Y | 1 |
| Clowes, JA; Eastell, R; Finigan, J; Naylor, KE; Paggiosi, MA; Peel, NF | 1 |
| Hamano, T | 1 |
| Ishimura, E; Okuno, S | 1 |
| Endo, I; Matsumoto, T | 1 |
| Buyukbayrak, EE; Kars, B; Karsidag, AY; Karsidag, C; Pirimoglu, M; Turan, MC; Unal, O | 1 |
| Akiyoshi, M; Kato, K; Kubota, T; Obayashi, S; Terauchi, M | 1 |
| Furumoto, H; Irahara, M; Kamada, M; Kaneyama, M; Kasai, Y; Kobayashi, A; Kuwahara, A; Maegawa, M; Matsui, S; Matsuzaki, T; Tani, A; Uemura, H; Yamamoto, S; Yasui, T | 1 |
| Boskey, AL; Calton, EF; Macleay, J | 1 |
| Bhat, KM; Nampurath, GK; Potu, BK; Rao, MS | 1 |
| Christodoulakos, GE; Creatsas, GC; Lambrinoudaki, IV; Panoulis, KP; Vourtsi, AD | 1 |
| Arangino, S; Cagnacci, A; Ibba, G; Melis, GB; Orrù, M; Paoletti, AM; Volpe, A; Zanni, A | 1 |
| Begerow, B; Minne, HW; Pfeifer, M; Pollähne, W | 1 |
| Alonzo, E; Bajares-Lilue, M; Bellorin-Font, E; Capriles, F; Carlini, R; Hernández, E; Martinis, R; Valera, R; Weisinger, JR | 1 |
| Felsenberg, D; Glüer, CC; Mühlenbacher, D; Nickelsen, T; Pavo, I; Payer, J; Quail, D; Reginster, JY; Resch, H; Schmitt, H; Stepan, J | 1 |
| Ettinger, B; Grove, MR; Hammond, CS; Hebert, GM; Moncur, MM; Pressman, AR; Ray, GT; Tosteson, AN | 1 |
| Black, DM; Downs, RW; Fuerst, T; Johnell, O; Kanis, JA; Pavo, I; Sarkar, S; Secrest, RJ | 1 |
| Dosik, M; Kaufman, R | 1 |
| Bryant, HU; Jee, WS; Ma, YL; Sato, M; Schmidt, A; Zeng, Q | 1 |
| Brown, SA; Rosen, CJ | 1 |
| Ma, KM; Mak, A; Mok, CC; To, CH | 1 |
| Matsuno, A; Okazaki, R; Okinaga, H | 1 |
| He, JW; Hu, YQ; Huang, QR; Li, M; Liu, YJ; Qin, YJ; Zhang, ZL | 1 |
| Fassbender, WJ; Kurth, A; Stumpf, UC | 1 |
| Broulík, PD; Broulíková, K | 1 |
| Clowes, JA; Eastell, R; Pereda, CA; Rogers, A | 1 |
| Barna, A; Bourgoin, M; Briot, K; Chapurlat, R; Christin-Maitre, S; Cortet, B; Costagliola, D; Diebolt, V; Dumarcet, N; Lacoin, F; Letombe, B; Nouyrigat, E; Oberlin, F; Orcel, P; Ravaud, P; Roux, C; Seret, P; Thomas, T; Veyries, ML; Vogel, JY; Yoldjian, I | 1 |
| Cremers, S; Garnero, P | 1 |
| Johnston, JA; Klein, R; Meadows, ES; Ohsfeldt, RL; Rousculp, MD; Smolen, L | 1 |
| Adami, S; Davis, SR; Delmas, PD; Hensen, J; Nijland, EA; van Os, S | 1 |
| Bryant, HU; Evans, GL; Magee, DE; Turner, RT | 1 |
| Bélanger, A; Labrie, C; Labrie, F; Martel, C; Picard, S; Richard, V | 1 |
| Duntas, LH; Koutras, DA; Mantzou, E | 1 |
| Bauss, F; Feldmann, S; Lempert, UG; Minne, HW; Parvizi, S; Pfeifer, M; Ziegler, R | 1 |
9 review(s) available for raloxifene hydrochloride and Low Bone Density
| Article | Year |
|---|---|
Systematic review of raloxifene in postmenopausal Japanese women with osteoporosis or low bone mass (osteopenia).
Topics: Aged; Aged, 80 and over; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Female; Fractures, Bone; Hip Joint; Humans; Lipids; Lumbar Vertebrae; Middle Aged; Osteoporosis, Postmenopausal; Quality of Life; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic | 2014 |
Pharmacotherapeutic management of osteoprosis and osteopenia.
Topics: Algorithms; Bone Density Conservation Agents; Bone Diseases, Metabolic; Calcitonin; Diphosphonates; Drug Monitoring; Estrogen Replacement Therapy; Fractures, Bone; Humans; Mass Screening; Nurse Practitioners; Nursing Assessment; Osteoporosis; Patient Selection; Practice Guidelines as Topic; Primary Health Care; Raloxifene Hydrochloride; Risk Assessment; Selective Estrogen Receptor Modulators; Teriparatide | 2009 |
[Effects of SERMs on bone health. The potential of SERM in the care of chronic kidney disease-mineral bone and disorders].
Topics: Bone Density Conservation Agents; Bone Diseases, Metabolic; Chronic Disease; Evidence-Based Medicine; Fractures, Spontaneous; Humans; Kidney Diseases; Osteoporosis; Parathyroid Hormone; Practice Guidelines as Topic; Raloxifene Hydrochloride; Risk; Selective Estrogen Receptor Modulators; Vitamin D | 2010 |
[Secondary osteoporosis UPDATE. Bone disease with decreased kidney function].
Topics: Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Chronic Disease; Diphosphonates; Fractures, Spontaneous; Humans; Kidney Diseases; Minerals; Raloxifene Hydrochloride; Reference Standards | 2010 |
[Secondary osteoporosis UPDATE. Drugs under development for metabolic bone disease].
Topics: Anabolic Agents; Bone Density Conservation Agents; Bone Diseases, Metabolic; Cathepsins; Diphosphonates; Drug Discovery; Humans; Osteoporosis; Raloxifene Hydrochloride; RANK Ligand; Selective Estrogen Receptor Modulators; Teriparatide | 2010 |
[Osteoporosis: prevention of bone loss and fractures].
Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Alendronate; Bone Diseases, Metabolic; Diagnosis, Differential; Exercise; Female; Fractures, Bone; Hip Fractures; Humans; Male; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risk Factors; Spinal Fractures; Time Factors; Tomography, X-Ray Computed | 2002 |
A rational approach to evidence gaps in the management of osteoporosis.
Topics: Age Factors; Aged; Animals; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone Resorption; Case Management; Cohort Studies; Diphosphonates; Drug Therapy, Combination; Estrogens; Evidence-Based Medicine; Female; Follow-Up Studies; Fractures, Spontaneous; Health Surveys; Hip Fractures; Humans; Incidence; Middle Aged; Osteoporosis, Postmenopausal; Parathyroid Hormone; Raloxifene Hydrochloride; Rats; Risk Assessment; Spinal Fractures; Time Factors | 2005 |
[Drug treatment of postmenopausal osteoporosis. What's New in 2006].
Topics: Absorptiometry, Photon; Adult; Age Factors; Aged; Aged, 80 and over; Alendronate; Body Mass Index; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Female; Femoral Fractures; Follow-Up Studies; Fractures, Bone; Humans; Middle Aged; Organometallic Compounds; Osteoporosis, Postmenopausal; Practice Guidelines as Topic; Raloxifene Hydrochloride; Risk Factors; Spinal Fractures; Tablets; Teriparatide; Thiophenes; Time Factors | 2006 |
Biochemical markers of bone turnover in the clinical development of drugs for osteoporosis and metastatic bone disease: potential uses and pitfalls.
Topics: Adrenal Cortex Hormones; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Biomarkers; Bone Density; Bone Diseases, Metabolic; Bone Neoplasms; Bone Remodeling; Bone Resorption; Calcitonin; Cathepsin K; Cathepsins; Collagen Type I; Denosumab; Diphosphonates; Drug Administration Schedule; Drug Design; Female; Humans; Organometallic Compounds; Osteitis Deformans; Osteogenesis; Osteoporosis; Osteoporosis, Postmenopausal; Parathyroid Hormone; Raloxifene Hydrochloride; RANK Ligand; Thiophenes | 2006 |
13 trial(s) available for raloxifene hydrochloride and Low Bone Density
| Article | Year |
|---|---|
Effect of raloxifene on parathyroid hormone in osteopenic and osteoporotic postmenopausal women with chronic kidney disease stage 5.
Topics: Administration, Oral; Alkaline Phosphatase; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Calcium; Female; Humans; Hyperparathyroidism, Secondary; Middle Aged; Osteoporosis, Postmenopausal; Parathyroid Hormone; Phosphorus; Raloxifene Hydrochloride; Renal Dialysis; Renal Insufficiency, Chronic | 2014 |
Response of bone turnover markers to raloxifene treatment in postmenopausal women with osteopenia.
Topics: Adult; Aged; Biomarkers; Bone Density; Bone Diseases, Metabolic; Bone Remodeling; Collagen Type I; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Postmenopause; Procollagen; Raloxifene Hydrochloride | 2016 |
Assessment of adherence to treatment of postmenopausal osteoporosis with raloxifene and/or alfacalcidol in postmenopausal Japanese women.
Topics: Aged; Aged, 80 and over; Biomarkers; Bone and Bones; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone Resorption; Drug Therapy, Combination; Female; Humans; Hydroxycholecalciferols; Japan; Medication Adherence; Middle Aged; Osteogenesis; Osteoporosis, Postmenopausal; Patient Dropouts; Raloxifene Hydrochloride; Statistics as Topic; Surveys and Questionnaires; Time Factors | 2010 |
The effect of cessation of raloxifene treatment on bone turnover in postmenopausal women.
Topics: Aged; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone Remodeling; Female; Humans; Middle Aged; Postmenopause; Raloxifene Hydrochloride; Treatment Outcome | 2010 |
Raloxifene: is it really effective on mood changes in postmenopausal osteopenic women?
Topics: Adult; Affective Symptoms; Bone Density Conservation Agents; Bone Diseases, Metabolic; Calcium, Dietary; Emotions; Female; Humans; Middle Aged; Postmenopause; Psychiatric Status Rating Scales; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators | 2010 |
Raloxifene does not modify insulin sensitivity and glucose metabolism in postmenopausal women.
Topics: Blood Glucose; Bone Diseases, Metabolic; C-Peptide; Estradiol; Female; Follicle Stimulating Hormone; Glucose Tolerance Test; Humans; Insulin; Italy; Middle Aged; Osteoporosis, Postmenopausal; Placebos; Postmenopause; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; White People | 2002 |
Effects of raloxifene on bone metabolism and serum lipids in postmenopausal women on chronic hemodialysis.
Topics: Aged; Bone and Bones; Bone Density; Bone Diseases, Metabolic; Estrogen Antagonists; Female; Humans; Kidney Failure, Chronic; Lipids; Middle Aged; Postmenopause; Prospective Studies; Raloxifene Hydrochloride; Renal Dialysis | 2003 |
Effect of raloxifene combined with monofluorophosphate as compared with monofluorophosphate alone in postmenopausal women with low bone mass: a randomized, controlled trial.
Topics: Adult; Aged; Analysis of Variance; Anthropometry; Bone Density; Bone Diseases, Metabolic; Double-Blind Method; Drug Therapy, Combination; Female; Fluorides; Fractures, Bone; Humans; Middle Aged; Osteoporosis, Postmenopausal; Phosphates; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators | 2003 |
Effect of raloxifene on the risk of new vertebral fracture in postmenopausal women with osteopenia or osteoporosis: a reanalysis of the Multiple Outcomes of Raloxifene Evaluation trial.
Topics: Aged; Bone Density; Bone Diseases, Metabolic; Estrogen Antagonists; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Postmenopause; Raloxifene Hydrochloride; Risk Factors; Risk Reduction Behavior; Spinal Fractures; Treatment Outcome | 2003 |
Raloxifene for postmenopausal women with systemic lupus erythematosus: a pilot randomized controlled study.
Topics: Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Female; Femur Neck; Humans; Lipids; Lumbar Vertebrae; Lupus Erythematosus, Systemic; Middle Aged; Pilot Projects; Postmenopause; Raloxifene Hydrochloride; Treatment Outcome | 2005 |
Association of bone metabolism related genes polymorphisms with the effect of raloxifene hydrochloride on bone mineral density and bone turnover markers in postmenopausal women with osteoporosis.
Topics: Aged; Biomarkers; Bone and Bones; Bone Density; Bone Diseases, Metabolic; Bone Remodeling; Double-Blind Method; Female; Humans; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Polymorphism, Genetic; Postmenopause; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Women | 2006 |
Effects of tibolone and raloxifene on bone mineral density in osteopenic postmenopausal women.
Topics: Aged; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone Remodeling; Collagen Type I; Double-Blind Method; Female; Hip Joint; Humans; Lumbar Vertebrae; Middle Aged; Norpregnenes; Osteocalcin; Osteoporosis, Postmenopausal; Peptides; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators | 2008 |
Lack of substantial effects of raloxifene on thyroxine-binding globulin in postmenopausal women: dependency on thyroid status.
Topics: Aged; Bone Diseases, Metabolic; Dose-Response Relationship, Drug; Female; Humans; Kinetics; Middle Aged; Osteoporosis, Postmenopausal; Postmenopause; Prospective Studies; Raloxifene Hydrochloride; Reference Values; Selective Estrogen Receptor Modulators; Thyroid Gland; Thyrotropin; Thyroxine; Thyroxine-Binding Proteins; Triiodothyronine | 2001 |
20 other study(ies) available for raloxifene hydrochloride and Low Bone Density
| Article | Year |
|---|---|
Sequential Treatment of Estrogen Deficient, Osteopenic Rats with Alendronate, Parathyroid Hormone (1-34), or Raloxifene Alters Cortical Bone Mineral and Matrix Composition.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Bone Diseases, Metabolic; Calcification, Physiologic; Collagen; Cortical Bone; Estrogens; Female; Osteocytes; Ovariectomy; Raloxifene Hydrochloride; Rats, Sprague-Dawley; Teriparatide | 2020 |
Treatment of Low Bone Density or Osteoporosis to Prevent Fractures in Men and Women: A Clinical Practice Guideline Update From the American College of Physicians.
Topics: Bone Diseases, Metabolic; Calcium, Dietary; Denosumab; Diphosphonates; Estrogen Replacement Therapy; Exercise; Female; Fractures, Bone; Humans; Male; Osteoporosis; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risk Factors; Teriparatide; Vitamin D | 2017 |
Selective estrogen receptor modulators and the vitamin D analogue eldecalcitol block bone loss in male osteoporosis.
Topics: Animals; Bone and Bones; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone Resorption; Indoles; Male; Mice; Mice, Inbred C57BL; Orchiectomy; Osteoporosis; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen; Testosterone; Vitamin D | 2017 |
Effects of raloxifene and hormone replacement therapy on forearm skin elasticity in postmenopausal women.
Topics: Aged; Bone Density Conservation Agents; Bone Diseases, Metabolic; Case-Control Studies; Elasticity; Estradiol; Estrogen Replacement Therapy; Female; Hot Flashes; Humans; Medroxyprogesterone Acetate; Middle Aged; Postmenopause; Raloxifene Hydrochloride; Skin | 2009 |
Raloxifene temporarily reduces arterial stiffness.
Topics: Aged; Ankle Brachial Index; Arteries; Atherosclerosis; Bone Diseases, Metabolic; Case-Control Studies; Elasticity; Female; Humans; Linear Models; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators | 2010 |
Effects of raloxifene on the production of cytokines in stimulated whole blood in ex vivo and in vitro studies.
Topics: Aged; Bone Density Conservation Agents; Bone Diseases, Metabolic; Cell Survival; Cytokines; Female; Humans; In Vitro Techniques; Leukocytes, Mononuclear; Menopause; Middle Aged; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Time Factors | 2011 |
Fourier transform infrared imaging analysis of cancellous bone in alendronate- and raloxifene-treated osteopenic sheep.
Topics: Alendronate; Animals; Bone and Bones; Bone Diseases, Metabolic; Raloxifene Hydrochloride; Sheep; Spectroscopy, Fourier Transform Infrared | 2011 |
Effect of Cissus quadrangularis Linn on the development of osteopenia induced by ovariectomy in rats.
Topics: Acid Phosphatase; Alkaline Phosphatase; Alkanes; Animals; Biomarkers; Bone Diseases, Metabolic; Bone Resorption; Calcium; Cissus; Disease Models, Animal; Drug Evaluation, Preclinical; Female; Femur; Humans; Hydroxyproline; Isoenzymes; Osteoporosis, Postmenopausal; Ovariectomy; Phytotherapy; Plant Extracts; Raloxifene Hydrochloride; Random Allocation; Rats; Rats, Wistar; Tartrate-Resistant Acid Phosphatase | 2011 |
Breast pain and mammographic density increase as a consequence of raloxifene therapy.
Topics: Bone Diseases, Metabolic; Breast; Female; Humans; Mammography; Middle Aged; Pain; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators | 2002 |
Early discontinuation of treatment for osteoporosis.
Topics: Alendronate; Bone Diseases, Metabolic; Breast Neoplasms; California; Cohort Studies; Estrogen Replacement Therapy; Female; Health Care Surveys; Health Knowledge, Attitudes, Practice; Heart Diseases; Humans; Interviews as Topic; Middle Aged; Osteoporosis; Raloxifene Hydrochloride; Treatment Refusal | 2003 |
Raloxifene rebound regression.
Topics: Antineoplastic Agents; Bone Diseases, Metabolic; Breast Neoplasms; Carcinoma, Ductal; Cyclophosphamide; Doxorubicin; Estrogen Antagonists; Female; Fluorouracil; Humans; Lung Neoplasms; Middle Aged; Raloxifene Hydrochloride; Remission Induction; Selective Estrogen Receptor Modulators; Tamoxifen | 2004 |
Raloxifene and teriparatide (hPTH 1-34) have complementary effects on the osteopenic skeleton of ovariectomized rats.
Topics: Animals; Bone Diseases, Metabolic; Bone Remodeling; Calcification, Physiologic; Drug Synergism; Estrogen Antagonists; Female; Injections, Subcutaneous; Lumbar Vertebrae; Ovariectomy; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley; Teriparatide | 2005 |
High risk of osteopenia and bone derangement in postsurgical patients with craniopharyngiomas, pituitary adenomas and other parasellar lesions.
Topics: Adolescent; Adult; Aged; Bone Density; Bone Diseases, Metabolic; Bone Resorption; Child; Collagen; Collagen Type I; Craniopharyngioma; Diphosphonates; Estrogens; Female; Follicle Stimulating Hormone; Gonadotropins; Humans; Hydrocortisone; Hypopituitarism; Luteinizing Hormone; Male; Middle Aged; Peptides; Pituitary Neoplasms; Raloxifene Hydrochloride; Risk Factors; Testosterone; Thyroxine | 2005 |
[The successful development of bisphosphonates in the therapy of osteoporosis].
Topics: Administration, Oral; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone Resorption; Diphosphonates; Estrogen Antagonists; Female; Humans; Male; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Primary Prevention; Raloxifene Hydrochloride; Risk Reduction Behavior | 2006 |
Raloxifen prevents bone loss in castrated male mice.
Topics: Animals; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Disease Models, Animal; Femur; Male; Mice; Orchiectomy; Organ Size; Raloxifene Hydrochloride; Seminal Vesicles; Testosterone | 2007 |
Different effects of raloxifene and estrogen on interleukin-1beta and interleukin-1 receptor antagonist production using in vitro and ex vivo studies.
Topics: Aged; Bone Diseases, Metabolic; Estradiol; Estrogen Antagonists; Estrogens; Female; Humans; Interleukin 1 Receptor Antagonist Protein; Interleukin-1beta; Leukocytes, Mononuclear; Middle Aged; Postmenopause; Raloxifene Hydrochloride | 2007 |
Cost-effectiveness of preventative therapies for postmenopausal women with osteopenia.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Bone Diseases, Metabolic; Breast Neoplasms; Cost-Benefit Analysis; Female; Fractures, Bone; Humans; Middle Aged; Models, Econometric; Quality-Adjusted Life Years; Raloxifene Hydrochloride; Risk; Thromboembolism | 2007 |
Raloxifene inhibits bone turnover and prevents further cancellous bone loss in adult ovariectomized rats with established osteopenia.
Topics: Animals; Bone and Bones; Bone Diseases, Metabolic; Dose-Response Relationship, Drug; Estrogen Antagonists; Ethinyl Estradiol; Female; Ovariectomy; Piperidines; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley | 1996 |
Prevention of bone loss by EM-800 and raloxifene in the ovariectomized rat.
Topics: Administration, Oral; Amino Acids; Animals; Benzopyrans; Bone Density; Bone Diseases, Metabolic; Bone Resorption; Cholesterol; Disease Models, Animal; Epithelial Cells; Estradiol; Estrogens; Female; Femur; Lumbar Vertebrae; Organ Size; Ovariectomy; Postmenopause; Propionates; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley; Tibia; Time Factors; Triglycerides; Uterus | 2000 |
Antiestrogen and antiandrogen administration reduce bone mass in the rat.
Topics: Androgen Antagonists; Animals; Bone Density; Bone Diseases, Metabolic; Cyproterone; Cyproterone Acetate; Estrogen Antagonists; Female; Hexestrol; Male; Orchiectomy; Ovariectomy; Piperidines; Raloxifene Hydrochloride; Rats; Tamoxifen; Testosterone | 1989 |